Every material Form 8-K Evolent Health, Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Evolent Health reported third-quarter 2026 revenue of $725.4 million, up from $479.5 million a year earlier, and a narrower net loss of $23.6 million, or $0.21 per share, versus $26.9 million, or $0.24 per share. The company raised its full-year 2026 Adjusted EBITDA guidance to $130.0 million to $135.0 million while reiterating its revenue guidance of $2.6 billion to $2.7 billion, though Adjusted EBITDA for the quarter fell to $34.3 million from $39.0 million.
Q3 2026 revenue $725.4 million vs. $479.5 million in Q3 2025; net loss attributable to common shareholders $23.6 million vs. $26.9 million
Adjusted EBITDA $34.3 million vs. $39.0 million; Adjusted EBITDA margin 4.7% vs. 8.1%; medical expense ratio 93.0% vs. 85.0%
2026 Adjusted EBITDA guidance raised to $130.0 million to $135.0 million; revenue guidance reiterated at $2.6 billion to $2.7 billion
Cash and cash equivalents $148.3 million as of September 30, 2026
Evolent Health reported second-quarter 2026 revenue of $652.5 million, up from $444.3 million a year earlier, and its net loss narrowed to $28.4 million from $51.1 million. Adjusted EBITDA fell to $28.1 million from $37.5 million, and the company raised its 2026 revenue guidance while tightening its Adjusted EBITDA range.
Q2 2026 revenue was $652.5 million versus $444.3 million in Q2 2025; net loss attributable to common shareholders was $28.4 million, or $0.25 per share, versus $51.1 million, or $0.44 per share.
Adjusted EBITDA was $28.1 million, with a 4.3% margin, compared with $37.5 million and an 8.5% margin a year earlier.
2026 revenue guidance was raised to $2.6 billion to $2.7 billion; Adjusted EBITDA guidance was tightened to $120 million to $135 million.
The company expects 2027 revenue growth of over 25% compared with 2026, and a 2027 Adjusted EBITDA midpoint at or above $150 million.
Evolent Health reported first-quarter 2026 revenue of $496.2 million, up from $483.6 million a year earlier, and a net loss attributable to common shareholders of $26.6 million, or $0.24 per share, versus $72.3 million, or $0.63 per share, a year earlier. Adjusted EBITDA fell to $22.1 million from $36.9 million, and the company reiterated its full-year 2026 revenue and Adjusted EBITDA guidance.
Q1 2026 revenue was $496.2 million versus $483.6 million in Q1 2025; net loss narrowed to $26.6 million from $72.3 million.
Adjusted EBITDA was $22.1 million (4.4% margin) versus $36.9 million (7.6% margin) a year earlier.
Full-year 2026 guidance was reiterated at $2.4 billion to $2.6 billion in revenue and approximately $110 million to $140 million in Adjusted EBITDA.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Evolent Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →